SG Americas Securities LLC raised its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 6.4% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 195,668 shares of the biotechnology company’s stock after buying an additional 11,839 shares during the quarter. SG Americas Securities LLC’s holdings in Biogen were worth $35,872,000 as of its most recent SEC filing.
Other institutional investors have also modified their holdings of the company. Reflection Asset Management acquired a new position in Biogen during the 4th quarter valued at about $25,000. WPG Advisers LLC raised its holdings in shares of Biogen by 417.9% during the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 117 shares during the last quarter. Accredited Wealth Management LLC grew its holdings in Biogen by 1,233.3% in the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after buying an additional 185 shares in the last quarter. First Horizon Corp bought a new position in shares of Biogen in the fourth quarter worth $30,000. Finally, WFA of San Diego LLC bought a new stake in shares of Biogen during the second quarter valued at about $32,000. Institutional investors own 87.93% of the company’s stock.
Analyst Upgrades and Downgrades
BIIB has been the subject of a number of recent analyst reports. Wedbush increased their target price on shares of Biogen from $191.00 to $196.00 and gave the company a “neutral” rating in a research report on Thursday, April 30th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Biogen in a report on Monday. Oppenheimer boosted their target price on Biogen from $275.00 to $300.00 and gave the stock an “outperform” rating in a report on Thursday, May 14th. Truist Financial decreased their price target on Biogen from $193.00 to $189.00 and set a “hold” rating for the company in a research note on Monday, April 13th. Finally, JPMorgan Chase & Co. boosted their price objective on Biogen from $175.00 to $185.00 and gave the stock a “neutral” rating in a research note on Thursday, April 23rd. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Biogen has a consensus rating of “Moderate Buy” and an average target price of $217.37.
Biogen Stock Down 1.3%
Shares of NASDAQ:BIIB opened at $197.19 on Wednesday. The firm has a 50 day simple moving average of $191.74 and a 200 day simple moving average of $185.19. Biogen Inc. has a 52 week low of $121.05 and a 52 week high of $205.97. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06. The company has a market cap of $29.11 billion, a PE ratio of 21.16 and a beta of 0.20.
Biogen (NASDAQ:BIIB – Get Free Report) last posted its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, topping the consensus estimate of $2.95 by $0.62. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The firm had revenue of $2.48 billion for the quarter, compared to analysts’ expectations of $2.29 billion. During the same period in the previous year, the company posted $3.02 EPS. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, research analysts expect that Biogen Inc. will post 13.95 earnings per share for the current year.
About Biogen
Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.
The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.
See Also
- Five stocks we like better than Biogen
- Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning
- Apple’s Intel Deal Arrives at the Right Time for Its Stock
- Liquid Gold: The AI Cooling Retrofit Trade
- 3 Dividend Stocks Under $30 to Anchor Your Portfolio
Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB – Free Report).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.
